Halozyme Therapeutics, Inc. (HALO)
64.49
-0.91
(-1.39%)
USD |
NASDAQ |
Apr 02, 16:00
64.49
0.00 (0.00%)
After-Hours: 19:01
Halozyme Therapeutics Research and Development Expense (TTM) : 81.49M for Dec. 31, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Johnson & Johnson | 14.72B |
| Skye Bioscience, Inc. | 41.64M |
| Eli Lilly & Co. | 13.34B |
| Stryker Corp. | 1.567B |
| Glaukos Corp. | 150.61M |